Japanese Phase 1 Study of BMS-844203 (CT322)
NCT01146171
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BMS-844203 (CT-322)
Sponsor
Bristol-Myers Squibb